Amphastar Pharmaceuticals Inc
AMPH27.120USD
+0.310+1.16%
收盘 12/26, 16:00（美东）报价延迟15分钟
1.26B总市值
11.50市盈率 TTM
关于 Amphastar Pharmaceuticals Inc 公司
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Amphastar Pharmaceuticals Inc简介
公司代码AMPH
公司名称Amphastar Pharmaceuticals Inc
上市日期Jun 25, 2014
CEOZhang (Yongfeng Yongfeng)
员工数量2028
证券类型Ordinary Share
年结日Jun 25
公司地址11570 6th St
城市RANCHO CUCAMONGA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编91730
电话19099809484
网址https://amphastar.com/
公司代码AMPH
上市日期Jun 25, 2014
CEOZhang (Yongfeng Yongfeng)
Amphastar Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
72.45K
-0.69%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
Mr. Jacob Liawatidewi
Mr. Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
--
--
Mr. Dan Dischner
Mr. Dan Dischner
Vice President - Corporate Communications
Vice President - Corporate Communications
--
--
Ms. Diane G. Gerst
Ms. Diane G. Gerst
Independent Director
Independent Director
--
--
Mr. David Gaugh
Mr. David Gaugh
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
72.45K
-0.69%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
United States
167.00M
95.75%
France
7.11M
4.08%
China
299.00K
0.17%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Applied Physics & Chemistry Laboratories, Inc.
14.86%
BlackRock Institutional Trust Company, N.A.
10.75%
Zhang (Jack Yongfeng)
5.71%
The Vanguard Group, Inc.
5.68%
TD Asset Management Inc.
4.20%
其他
58.80%
持股股东
持股股东
占比
Applied Physics & Chemistry Laboratories, Inc.
14.86%
BlackRock Institutional Trust Company, N.A.
10.75%
Zhang (Jack Yongfeng)
5.71%
The Vanguard Group, Inc.
5.68%
TD Asset Management Inc.
4.20%
其他
58.80%
股东类型
持股股东
占比
Investment Advisor
40.55%
Investment Advisor/Hedge Fund
22.63%
Corporation
14.86%
Individual Investor
9.43%
Hedge Fund
6.47%
Research Firm
2.82%
Pension Fund
1.06%
Bank and Trust
0.34%
Sovereign Wealth Fund
0.12%
其他
1.72%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
586
33.97M
85.20%
+16.67K
2025Q3
603
33.96M
84.80%
+202.84K
2025Q2
607
33.74M
83.87%
-544.61K
2025Q1
597
34.53M
80.40%
-3.80M
2024Q4
593
35.69M
79.40%
-112.11K
2024Q3
575
35.68M
75.48%
+965.70K
2024Q2
565
34.64M
73.86%
+833.26K
2024Q1
548
33.97M
73.49%
-1.92M
2023Q4
531
33.91M
72.12%
+1.03M
2023Q3
499
32.97M
71.03%
+509.94K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Applied Physics & Chemistry Laboratories, Inc.
6.83M
14.68%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.12M
11.02%
-399.35K
-7.23%
Jun 30, 2025
Zhang (Jack Yongfeng)
2.62M
5.64%
+200.00K
+8.25%
Jun 13, 2025
The Vanguard Group, Inc.
2.67M
5.73%
+251.01K
+10.40%
Jun 30, 2025
TD Asset Management Inc.
2.03M
4.38%
-177.21K
-8.01%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.63M
3.5%
+270.52K
+19.94%
Jun 30, 2025
State Street Investment Management (US)
1.58M
3.39%
-28.38K
-1.77%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
1.26M
2.72%
+174.00
+0.01%
Jun 30, 2025
Boston Trust Walden Company
1.18M
2.53%
-39.17K
-3.22%
Jun 30, 2025
Epoch Investment Partners, Inc.
1.24M
2.67%
-19.94K
-1.58%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco Pharmaceuticals ETF
2.25%
State Street SPDR S&P Pharmaceuticals ETF
1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.38%
Invesco S&P SmallCap 600 GARP ETF
1.12%
Acquirers Small and Micro Deep Value ETF
0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.77%
Invesco S&P SmallCap Health Care ETF
0.56%
First Trust Small Cap Value AlphaDEX Fund
0.5%
Distillate Small/Mid Cash Flow ETF
0.45%
VictoryShares Small Cap Free Cash Flow ETF
0.37%
查看更多
Invesco Pharmaceuticals ETF
占比2.25%
State Street SPDR S&P Pharmaceuticals ETF
占比1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.38%
Invesco S&P SmallCap 600 GARP ETF
占比1.12%
Acquirers Small and Micro Deep Value ETF
占比0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
占比0.77%
Invesco S&P SmallCap Health Care ETF
占比0.56%
First Trust Small Cap Value AlphaDEX Fund
占比0.5%
Distillate Small/Mid Cash Flow ETF
占比0.45%
VictoryShares Small Cap Free Cash Flow ETF
占比0.37%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Amphastar Pharmaceuticals Inc的前五大股东是谁？
Amphastar Pharmaceuticals Inc 的前五大股东如下：
Applied Physics & Chemistry Laboratories, Inc.持有股份：6.83M，占总股份比例：14.68%。
BlackRock Institutional Trust Company, N.A.持有股份：5.12M，占总股份比例：11.02%。
Zhang (Jack Yongfeng)持有股份：2.62M，占总股份比例：5.64%。
The Vanguard Group, Inc.持有股份：2.67M，占总股份比例：5.73%。
TD Asset Management Inc.持有股份：2.03M，占总股份比例：4.38%。
Applied Physics & Chemistry Laboratories, Inc.持有股份：6.83M，占总股份比例：14.68%。
BlackRock Institutional Trust Company, N.A.持有股份：5.12M，占总股份比例：11.02%。
Zhang (Jack Yongfeng)持有股份：2.62M，占总股份比例：5.64%。
The Vanguard Group, Inc.持有股份：2.67M，占总股份比例：5.73%。
TD Asset Management Inc.持有股份：2.03M，占总股份比例：4.38%。
Amphastar Pharmaceuticals Inc的前三大股东类型是什么？
Amphastar Pharmaceuticals Inc 的前三大股东类型分别是：
Applied Physics & Chemistry Laboratories, Inc.
BlackRock Institutional Trust Company, N.A.
Zhang (Jack Yongfeng)
Applied Physics & Chemistry Laboratories, Inc.
BlackRock Institutional Trust Company, N.A.
Zhang (Jack Yongfeng)
有多少机构持有Amphastar Pharmaceuticals Inc(AMPH)的股份？
截至2025Q4，共有586家机构持有Amphastar Pharmaceuticals Inc的股份，合计持有的股份价值约为33.97M，占公司总股份的85.20%。与2025Q3相比，机构持股有所增加，增幅为0.40%。
哪个业务部门对Amphastar Pharmaceuticals Inc的收入贡献最大？
在FY2025Q2，--业务部门对Amphastar Pharmaceuticals Inc的收入贡献最大，创收--，占总收入的--%。
